A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS).

ABSTRACT:

Objective

To determine the efficacy and safety of eculizumab for patients with atypical haemolytic uraemic syndrome (aHUS), compared with current treatment options.

Design

A systematic review was performed according to the general principles of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. All study designs were included, except case histories.

Participants

All patients diagnosed with aHUS were included; no age restrictions were used.

Interventions

Eculizumab compared with current treatment options.

Identification of studies

12 databases were searched. Additional searches were performed through the Food and Drug Administration (FDA) and the Electronic Medicines Compendium websites, Google internet searches and

SUBMITTER: Rathbone J 

PROVIDER: S-EPMC3822313 | biostudies-literature | 2013 Nov

REPOSITORIES: biostudies-literature